#USA #New York #Gross Law Firm #Securities Class Action #Unicycive Therapeutics

Important Notice for Unicycive Therapeutics Investors

The Gross Law Firm has released a critical notice aimed at shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY), urging those who purchased shares during a specified period to reach out before October 14, 2025. This outreach is essential for discussing potential rights and actions available to them as investors.

Why Contact The Gross Law Firm?

Investors who bought UNCY shares between March 29, 2024, and June 27, 2025, are encouraged to engage with The Gross Law Firm regarding possibilities for lead plaintiff appointments in an ongoing class action lawsuit. It's important to note that becoming a lead plaintiff is entirely voluntary and not a requirement for participation in any recovery from the case.

Reports indicate that shareholders are facing significant concerns regarding misleading company statements. Allegations suggest that Unicycive overstated its compliance with FDA manufacturing standards and the regulatory forecasts associated with its oxylanthanum carbonate drug application. As such, investors may be at risk due to potential misinformation impacting the company’s stock value.

Allegations Against Unicycive Therapeutics

The complaint outlines several key allegations against Unicycive's management, emphasizing that during the mentioned class period, they allegedly provided false or misleading statements regarding their operational readiness and overall regulatory compliance with FDA requirements. Furthermore, it claims that this oversight inflated the company's public perception, directly affecting share price and investor decisions.

Next Steps for Shareholders

Shareholders are advised not to delay in registering for this class action, ensuring they are kept informed of any developments regarding their investments. By registering, shareholders will gain access to portfolio monitoring software, which will deliver updates through the lifecycle of the case. The cutoff date to seek lead plaintiff status is set for October 14, 2025. Importantly, participating in this case incurs no cost or obligation to the investors. All concerned shareholders can register through the provided link or contact the firm directly for further assistance.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized entity specializing in class action lawsuits. Their mission revolves around safeguarding the rights of investors who may have experienced significant losses due to deceitful practices and illegal business conduct. They are dedicated to prompting corporations to follow ethical practices and promote responsible corporate citizenship. The firm aspires to recover funds for investors whose financial stability has been compromised due to misleading information.

How to Contact The Gross Law Firm

For any inquiries or assistance regarding your rights as an investor or to discuss potential participation in this class action, reach out to The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

It is crucial for shareholders involved with Unicycive Therapeutics, Inc. to stay informed and proactive regarding their investments as the deadline approaches. Being aware of these developments may provide avenues for recovery and protect their financial interests in the face of corporate mismanagement.